Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMIX neoadjuvant epirubicin + docetaxel + Avastin in breast cancer
2007-005858-23Phase 2Active
- Sponsor
- PROMIX Trial Group
- Start
- Dec 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, epirubicin and docetaxel in breast cancer and inflammatory breast cancer (IBC), sponsored by PROMIX Trial Group. Primary endpoints: Objective response and Early detection of response or non-response. Started Dec 2007; status: active.
02
Drugs
bevacizumabepirubicindocetaxel
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2007-005858-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005858-23.